NovoCure Limited Stock News

NovoCure Limited (NASDAQ:NVCR ) Q2 2023 Earnings Conference Call July 27, 2023 8:00 AM ET Company Participants Ingrid Goldberg - VP of IR William Doyle - Executive Chairman Asaf Danziger - CEO Ashley

In early June, NovoCure's stock dropped 43% in a single day after the company presented the LUNAR study at ASCO. The stock now trades near 5-year lows. What caused the drop exactly? And is this the en

Novocure published the results of an important phase 3 clinical trial last month. The treatment clearly demonstrated strong results that improved outcomes for lung cancer patients.

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2023 on Thursday, July 27, 2023, before the U.S. fina

Major large cap pharmaceutical firms often dominate the headlines. However, small cap drug companies also contribute significantly to scientific advancements.

Novocure sells a cancer treatment that is already popular among patients with brain cancer. Brain cancer is relatively rare, so investors are hoping an expansion to the larger lung cancer indication w

Novocure Ltd (NASDAQ:NVCR) is up 2% to trade at $46.08 this morning, amid concerns around the commercial use of its experimental device to treat a  type of lung cancer , which extended overall survi

NovoCure Limited's primary endpoint of phase 3 LUNAR study, using TTFields plus standard therapies for 2nd line metastatic NSCLC patients, was met with statistical significance with p-value of p=0.035

The Nasdaq moved higher on Tuesday afternoon. NovoCure shares fell despite favorable data from a phase 3 clinical trial.

NovoCure announced positive results for its Tumor Treating Fields in treating non-small cell lung cancer. However, analysts raised concerns that the data doesn't reflect how patients are treated in th

Novocure said on Tuesday its experimental device to treat a type of lung cancer showed a statistically significant improvement in extending overall survival among patients in a late-stage study.

CRISPR Therapeutics could soon win approval for its first product. Novocure has big news on the way in a matter of days.

The case against Novocure centers on its declining sales and uncertainty about expanding into new markets. The case for Novocure focuses on the company's huge prospects if its late-stage clinical stud

In discussing healthcare tech stocks, it pays to understand what healthcare technology is broadly. Healthcare technology, also known as HealthTech, refers to any technology developed to improve the he

NovoCure has seen strong growth over the past decade but is unable to post profits with large sums invested into the pipeline. After softer sales momentum, pipeline conversion to other cancer types is